Wall Street brokerages predict that NewLink Genetics Corp (NASDAQ:NLNK) will announce sales of $5.78 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for NewLink Genetics’ earnings, with estimates ranging from $5.00 million to $7.35 million. NewLink Genetics posted sales of $2.76 million in the same quarter last year, which suggests a positive year over year growth rate of 109.4%. The business is expected to announce its next earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that NewLink Genetics will report full year sales of $19.37 million for the current fiscal year, with estimates ranging from $18.10 million to $20.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $11.37 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow NewLink Genetics.
NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.32. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. The business had revenue of $10.10 million for the quarter, compared to the consensus estimate of $2.72 million.
NLNK has been the topic of several research analyst reports. Cantor Fitzgerald set a $26.00 target price on NewLink Genetics and gave the stock a “buy” rating in a research note on Friday, March 2nd. Jefferies Group downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Friday, April 6th. Bank of America downgraded NewLink Genetics from a “buy” rating to a “neutral” rating in a research note on Friday, April 6th. Robert W. Baird downgraded NewLink Genetics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $22.00 to $5.00 in a research note on Monday, April 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a $21.00 target price (down from $25.00) on shares of NewLink Genetics in a research note on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $12.86.
A number of hedge funds have recently made changes to their positions in NLNK. Raymond James Financial Services Advisors Inc. acquired a new stake in NewLink Genetics during the 4th quarter worth about $118,000. The Manufacturers Life Insurance Company lifted its position in NewLink Genetics by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares during the period. Creative Planning acquired a new stake in NewLink Genetics during the 4th quarter worth about $152,000. Acadian Asset Management LLC lifted its position in NewLink Genetics by 241.6% during the 4th quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 13,770 shares during the period. Finally, Raymond James & Associates acquired a new stake in NewLink Genetics during the 4th quarter worth about $240,000. Hedge funds and other institutional investors own 65.05% of the company’s stock.
NLNK stock traded down $0.02 on Tuesday, hitting $4.49. 794,847 shares of the company’s stock were exchanged, compared to its average volume of 1,913,055. NewLink Genetics has a 12-month low of $3.75 and a 12-month high of $19.47. The company has a market cap of $166.83, a price-to-earnings ratio of -1.95 and a beta of 1.22.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.